JP2006348050A - Medicine and health food composition for promoting bloodstream by vasolidation - Google Patents

Medicine and health food composition for promoting bloodstream by vasolidation Download PDF

Info

Publication number
JP2006348050A
JP2006348050A JP2006254370A JP2006254370A JP2006348050A JP 2006348050 A JP2006348050 A JP 2006348050A JP 2006254370 A JP2006254370 A JP 2006254370A JP 2006254370 A JP2006254370 A JP 2006254370A JP 2006348050 A JP2006348050 A JP 2006348050A
Authority
JP
Japan
Prior art keywords
protein
peptide
health food
food composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006254370A
Other languages
Japanese (ja)
Inventor
Hiroshi Hagino
浩志 萩野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHIRAKO KK
Shirako Co Ltd
Original Assignee
SHIRAKO KK
Shirako Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHIRAKO KK, Shirako Co Ltd filed Critical SHIRAKO KK
Priority to JP2006254370A priority Critical patent/JP2006348050A/en
Publication of JP2006348050A publication Critical patent/JP2006348050A/en
Pending legal-status Critical Current

Links

Images

Abstract

<P>PROBLEM TO BE SOLVED: To provide a new material that exhibits a vasolidative action thereby to suppress or alleviate various human diseases or disorders. <P>SOLUTION: The composition comprises as an effective ingredient a peptide obtained by hydrolyzing a protein derived from a milk protein selected from among skim milk powders and whey. The composition is used as a medicinal composition or a health food composition and exhibits vasolidation effects thereby to suppress or improve various symptoms such as stiff shoulders, headache or cold constitution associated with lowering of bloodstream. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

本発明は、血管拡張作用を有し、それにより肩凝り、頭痛、冷え症およびそれに関連する機態低下症状を抑制、改善することができる医薬および健康食品組成物に関し、さらに詳しくは、ミルクタンパク由来のタンパク質を加水分解して得られたペプチドを有効成分とする上記医薬および健康食品組成物に関する。   The present invention relates to a pharmaceutical and health food composition having a vasodilatory effect, thereby suppressing and improving stiff shoulders, headaches, coldness and related hypomorphic symptoms, and more particularly, derived from milk protein It is related with the said pharmaceutical and health food composition which use the peptide obtained by hydrolyzing protein of this as an active ingredient.

血液循環を改善することは、肩凝り、冷え性、頭痛、手足のしびれなどの症状の改善、疲労回復、末端組織および毛髪の新陳代謝の促進に繋がる。血液循環の改善により、全体としては末端組織に酸素、栄養が十分行き渡り、炭酸ガス、乳酸など老廃物が回収され、入浴後のような心地よい状態になり、身体が温まり、疲労、神経痛、更年期障害が解消するなどの症状が改善される。   Improving blood circulation leads to improvement of symptoms such as stiff shoulders, coolness, headache, numbness of limbs, recovery from fatigue, and promotion of end tissue and hair metabolism. Improvement of blood circulation as a whole, oxygen and nutrients are adequately distributed to the end tissues, and waste products such as carbon dioxide and lactic acid are collected, making it comfortable after bathing, warming the body, fatigue, neuralgia, climacteric disorder Symptoms such as disappearance are improved.

血流を促進するメカニズムは幾つかある。一つは赤血球の変形能向上による血液流動性の増加であり、もう一つは血管を拡張することによる血流量の増加である。前者に関する従来技術としては、例えばナツメおよびその抽出物により赤血球の変形能低下を防止するものがあり(特許文献1および特許文献2参照)、また、赤血球、白血球、血小板など血液成分の粘性を下げ、血液流動性を改善するコラーゲンペプチドに関する報告もある(特許文献3参照)。   There are several mechanisms that promote blood flow. One is an increase in blood fluidity by improving the deformability of red blood cells, and the other is an increase in blood flow by dilating blood vessels. As the prior art related to the former, there is, for example, a method that prevents a reduction in deformability of erythrocytes by jujube and its extract (see Patent Document 1 and Patent Document 2), and lowers the viscosity of blood components such as red blood cells, white blood cells, and platelets. There is also a report on a collagen peptide that improves blood fluidity (see Patent Document 3).

また、次のような各種天然物またはその抽出物による血流改善効果の報告があるが、その血流改善のメカニズムについては必ずしも明確ではない。例えば、サフランまたはサフランの抽出物(特許文献4参照)、タンポポとヨモギのエキス(特許文献5参照)、牛の内臓と骨を粥状に煮沸したもの(特許文献6参照)、蓮根の節と根毛の焼焦物(特許文献7参照)、ムラサキサツマイモの水溶性抽出物(特許文献8参照)、テアニン含有物(特許文献9参照)、地黄(特許文献10参照)、イヌゴマのサポニン(特許文献11参照)の例が知られている。   Moreover, although the following various natural products or the extract of the blood flow improvement effect has been reported, the mechanism of the blood flow improvement is not necessarily clear. For example, saffron or saffron extract (see Patent Document 4), dandelion and mugwort extract (see Patent Document 5), boiled bovine viscera and bone (see Patent Document 6), lotus root knot Scallops of root hair (see patent document 7), water-soluble extract of purple sweet potato (see patent document 8), theanine-containing material (see patent document 9), ground yellow (see patent document 10), saponin of sesame seed (patent document) 11) is known.

また、血管拡張の認められた例としてはウサギの耳の血管をイワシ筋肉由来ペプチドが拡張することが報告されている(特許文献12参照)。しかし、現象面だけの報告であって、人に対する有効例の報告や用途については記載されていない。
近年、種々の血流改善メカニズムによる血流改善物質の更なる開発が求められている。
特開平05−210639号公報 特開平07−61933号公報 特許第3197547号明細書 特開平10−287576号公報 特開昭60−160856号公報 特開昭54−41354号公報 特開昭53−133646号公報 特開2001−145471号公報 特開2000−247878号公報 特開2000−169385号公報 特開平07−233191号公報 特許2732056号明細書
In addition, as an example in which vasodilation is observed, it has been reported that a peptide derived from sardine muscle expands a blood vessel of a rabbit ear (see Patent Document 12). However, it is a report only on the phenomenon side, and does not describe a report of an effective example for a person or a use.
In recent years, further development of blood flow improving substances by various blood flow improving mechanisms has been demanded.
Japanese Patent Laid-Open No. 05-210639 JP 07-61933 A Japanese Patent No. 3197547 Japanese Patent Laid-Open No. 10-287576 JP-A-60-160856 JP 54-41354 A JP-A-53-133646 JP 2001-145471 A JP 2000-247878 A JP 2000-169385 A JP 07-233191 A Japanese Patent No. 2732056

本発明は、血管を拡張する作用を有し、それによって血液循環を改善して肩凝り、冷え性、頭痛、疲労、更年期障害を抑制または軽減し、新陳代謝を促進する新規素材を提供することを目的とし、さらにかかる作用を有する健康食品、医薬品を提供することを目的とする。   An object of the present invention is to provide a novel material that has an action of dilating blood vessels, thereby improving blood circulation, suppressing or reducing shoulder stiffness, coldness, headache, fatigue, climacteric disorder, and promoting metabolism. Furthermore, an object of the present invention is to provide health foods and pharmaceuticals having such actions.

本発明者は、脱脂粉乳およびホエーから選ばれたミルクタンパク由来のタンパク質を加水分解して得たペプチド類を主体とする成分を、ウサギの耳の血管を用いてスクリーニングした結果、これらのペプチド類に血管を拡張する効果が存在することを見出した。すなわち、上記タンパク質の酸またはアルカリによる加水分解、および/または酵素プロテアーゼによる加水分解により得られるペプチド類を含む成分を、そのまま、または精製して、ウサギに経口投与して血管の拡張を確認した。   As a result of screening the components mainly composed of peptides obtained by hydrolyzing a protein derived from milk protein selected from skim milk powder and whey using blood vessels of rabbit ears, these peptides It has been found that there is an effect of dilating blood vessels. That is, components containing peptides obtained by hydrolysis of the protein with acid or alkali and / or hydrolysis with enzyme protease were orally purified as they were orally administered to rabbits to confirm vascular dilation.

これらのウサギの耳で認められた血管拡張は血流の増加に繋がり、その結果、血圧低下効果、肩凝り、冷え性および頭痛の改善効果、疲労回復効果、更年期障害の抑制および軽減効果、新陳代謝の促進による育毛効果、皮膚の状態改善効果など幅広い効果が確認された。   Vasodilation observed in the ears of these rabbits leads to increased blood flow, resulting in blood pressure lowering effects, stiff shoulders, cooling and headache improvement effects, fatigue recovery effects, climacteric disorder suppression and alleviation effects, metabolic effects A wide range of effects were confirmed, including hair-growth effect by promotion and skin condition improvement effect.

したがって本発明は、上記タンパク質の加水分解により得られたペプチドを有効成分とする血管拡張による血流促進性医薬および健康食品組成物に関する。   Therefore, the present invention relates to a blood flow-promoting pharmaceutical and health food composition by vasodilation, which comprises a peptide obtained by hydrolysis of the protein as an active ingredient.

本発明においてタンパク質の加水分解は、酸またはアルカリによる分解、プロテアーゼを用いる酵素分解が一般的に用いられる。酸またはアルカリは、有機、無機いずれの酸、アルカリを用いてもよく、酸加水分解の場合はpH1〜4の範囲、アルカリ加水分解の場合はpH8〜13の範囲が好ましい。分解時の温度、時間などの反応条件は適宜設定する。   In the present invention, protein hydrolysis is generally performed by acid or alkali decomposition or enzymatic decomposition using a protease. As the acid or alkali, any of organic and inorganic acids and alkalis may be used. In the case of acid hydrolysis, a pH of 1 to 4 is preferable, and in the case of alkaline hydrolysis, a pH of 8 to 13 is preferable. Reaction conditions such as temperature and time during decomposition are appropriately set.

プロテアーゼとしては、ペプシン、パンクレアチン、パパイン、プロレザー(天野製薬社製)、サモアーゼ(大和化成社製)、スミチームAP、スミチームMP、スミチームFP(いずれも新日本化学社製)、その他、一般的に用いられるプロテアーゼ活性を有する酵素を用いることができる。反応の際、酵素の使用濃度、反応のpHや反応温度、その他の条件などは、各酵素剤毎に最適な条件を選択すればよい。   Proteases include pepsin, pancreatin, papain, pro leather (manufactured by Amano Pharmaceutical Co., Ltd.), Samoaase (manufactured by Daiwa Kasei Co., Ltd.), Sumiteam AP, Sumiteam MP, Sumiteam FP (all manufactured by Shin Nippon Chemical Co., Ltd.), and other general An enzyme having protease activity used in the above can be used. In the reaction, the optimum concentration of the enzyme, reaction pH, reaction temperature, and other conditions may be selected for each enzyme agent.

酸、アルカリによる加水分解では、反応の進行を一定に調節することは必ずしも易しくはない。したがって厳密な反応管理が必要である。さらに、酸またはアルカリによる加水分解処理と酵素による加水分解を併用することができる。酸またはアルカリによる処理後、続いてタンパク分解酵素処理を行うことによって、ペプチドの低分子化が進み、低分子ペプチド類の比率が高まる。低分子のペプチドは消化管で吸収され易く、血管拡張効果が高いので、このようにして低分子ペプチドの比率を高めることが望ましい。ただ、人の消化管内では高分子のペプチドも消化管のペプシン、トリプシン、およびペプチダーゼにより低分子ペプチドを生成するため、低分子以外のペプチドでも効果が認められる。しかし、低分子ペプチドの方が短時間で確実に効果の発現するものと考えられる。したがって、ペプチドの分子量については、低分子ペプチドの比率の高い方が望ましいが、食品として利用する場合は中、高分子ペプチドを含んでいても同様に血管拡張の効果が認められる。   In hydrolysis with acid or alkali, it is not always easy to adjust the progress of the reaction to a certain level. Therefore, strict reaction management is necessary. Furthermore, hydrolysis treatment with an acid or alkali and hydrolysis with an enzyme can be used in combination. Subsequent treatment with an acid or alkali followed by proteolytic enzyme treatment leads to a reduction in the molecular weight of the peptide and an increase in the proportion of low molecular weight peptides. Since a low molecular weight peptide is easily absorbed in the digestive tract and has a high vasodilator effect, it is desirable to increase the ratio of the low molecular weight peptide in this way. However, in the human gastrointestinal tract, high-molecular peptides also generate low-molecular-weight peptides by pepsin, trypsin, and peptidase in the gastrointestinal tract. However, it is considered that the effect of the low molecular peptide is surely exhibited in a short time. Therefore, the molecular weight of the peptide is preferably higher in the ratio of the low molecular weight peptide, but when used as a food, the effect of vasodilation is recognized even if the polymer peptide is contained.

各タンパク質の加水分解によって得られたペプチド成分は反応物をそのまま用いてもよいが、ペプチド成分を濃縮精製して用いてもよい。濃縮精製処理は、電気透析膜による脱塩処理、イオン交換樹脂による脱塩・濃縮処理、活性炭による脱色、脱臭および濃縮処理、有機溶媒による沈殿処理により行うことができる。それぞれの成分は液体のまま用いてもよいが、噴霧乾燥、凍結乾燥を施すことによって粉末化することもできる。また、クロマトグラフィーを用いて更に精製したものを用いることもできる。   As the peptide component obtained by hydrolysis of each protein, the reaction product may be used as it is, or the peptide component may be concentrated and purified. The concentration and purification treatment can be performed by a desalting treatment using an electrodialysis membrane, a desalting / concentration treatment using an ion exchange resin, a decolorization using activated carbon, a deodorizing and concentration treatment, or a precipitation treatment using an organic solvent. Each component may be used as it is, but can also be pulverized by spray drying or freeze drying. Moreover, what was further purified using chromatography can also be used.

加水分解処理される上記タンパク質原料は上記ミルクタンパク質原料をそのまま用いることもできるが、原料に脂肪分が多い場合は、分解物中に脂肪分が残って酸化を受け、異臭、異味を発生したりすることが多いので、精製されたタンパク質であることが望ましい。したがって、予め油分を分離した原材料を利用することが望ましい。   The milk protein raw material can be used as it is as the protein raw material to be hydrolyzed. However, if the raw material has a large amount of fat, the fat remains in the decomposed product and is oxidized to generate a strange odor or taste. Therefore, it is desirable that the protein be purified. Therefore, it is desirable to use raw materials from which oil has been separated in advance.

血管の拡張効果の確認はウサギの耳を用いて行った。すなわち、ウサギに試料を経口投与し、耳の血管の変化を視覚的に確認し、その写真から面積計算ソフトを使って血管拡張の程度の数値化を行った。以下に示す実施例ではすべてこの方法により血管拡張効果を確認した。   The confirmation of the vasodilator effect was performed using rabbit ears. That is, a sample was orally administered to a rabbit, the change of the ear blood vessel was visually confirmed, and the degree of vasodilation was quantified using the area calculation software from the photograph. In all the examples shown below, the vasodilator effect was confirmed by this method.

本発明においては、ミルクタンパク由来のタンパク質の加水分解物による血管の血管拡張の結果、血流が増加し、それによって栄養分の末端組織への移行が改善されると共に老廃物の移行も改善されるものと推定される。その結果、ヒトで肩凝り、頭痛、冷え性の抑制、軽減の目的に使用できる。また、血液循環の改善によって、循環器系のみならず神経系、内分泌系、免疫系の関係する生理機能の改善もはかられ、睡眠障害、更年期障害の抑制および改善を目的に使用できる。また、末梢組織からの炭酸ガス、乳酸その他老廃物を適宜回収し、末梢組織への酸素、栄養成分が十分に供給されることから、疲労回復、さらには皮膚状態の改善、美容効果、育毛効果も得られる。これらの効果についてはヒトでの試験の結果を実施例として示した。   In the present invention, vascular vasodilation by a protein hydrolyzate derived from milk protein results in increased blood flow, thereby improving the transfer of nutrients to the end tissue and improving the transfer of waste products. Estimated. As a result, it can be used for the purpose of suppressing or reducing stiff shoulders, headaches, and coldness in humans. In addition, improvement of blood circulation can improve physiological functions related to not only the circulatory system but also the nervous system, endocrine system, and immune system, and can be used for the purpose of suppressing and improving sleep disorders and climacteric disorders. In addition, carbon dioxide, lactic acid and other waste products from peripheral tissues are collected as appropriate, and oxygen and nutritional components are sufficiently supplied to the peripheral tissues, so that fatigue recovery, skin condition improvement, cosmetic effects, and hair growth effects are achieved. Can also be obtained. About these effects, the result of the test in a human was shown as an Example.

本発明の上記ミルクタンパク由来タンパク質加水分解物の使用態様としては、食品添加剤として一般食品に添加したり、健康食品組成物または医薬組成物として用いることができる。また、上記タンパク質の加水分解物の形態は、水溶液、懸濁物、粉末、固体成型物などいずれでもよく、特に限定されない。したがって、幅広い一般食品に添加使用出来るし、健康食品、医薬品としてはカプセル剤、錠剤、粉末剤、顆粒剤、ドリンク剤などとして提供される。その場合に単味成分として使用するのみならず、他の呈味成分、増量剤、安定剤、および生薬、ハーブなどの機能性素材やその機能性成分と混合、併用して用いることができ、また、ビタミン、ミネラルなど栄養成分、食品として許容される素材などと混合、併用して用いることもできる。   As a use aspect of the said milk protein origin protein hydrolyzate of this invention, it can add to a general food as a food additive, and can be used as a health food composition or a pharmaceutical composition. The form of the protein hydrolyzate may be any of an aqueous solution, a suspension, a powder, a solid molding, and the like, and is not particularly limited. Therefore, it can be used in a wide range of general foods, and as health foods and pharmaceuticals, it is provided as capsules, tablets, powders, granules, drinks and the like. In that case, it can be used not only as a simple ingredient, but also in combination with other taste ingredients, bulking agents, stabilizers, and functional materials such as herbal medicines and herbs and their functional ingredients, Moreover, it can also be used by mixing with nutrient components such as vitamins and minerals, and materials acceptable as food.

これらの効果を発揮させるためのヒトでの投与量はタンパク質加水分解物として0.5〜2000mg/kg・日が好ましく、10〜400mg/kg・日が更に好ましい。ただし、症状の種類、度合いには個人差があるため、かかる範囲に限定されるものではない。   The dose for humans to exert these effects is preferably 0.5 to 2000 mg / kg · day, more preferably 10 to 400 mg / kg · day as a protein hydrolyzate. However, since there are individual differences in the type and degree of symptoms, it is not limited to this range.

本発明によれば、脱脂粉乳およびホエーから選ばれたミルクタンパク質を加水分解して得られたペプチドを含有する組成物を医薬および健康食品に用いることによって、血管拡張効果を奏することができ、それにより肩凝り、頭痛、冷え症およびそれに関連する機態低下症状を抑制、改善することができる。   According to the present invention, a composition containing a peptide obtained by hydrolyzing milk protein selected from skim milk powder and whey can be used for pharmaceuticals and health foods to exert a vasodilator effect, Can suppress and ameliorate stiff shoulders, headaches, coldness and related symptoms of hypofunction.

以下に本発明の実施の態様を製造例、実施例を示し、説明する。
(製造例1)
畜乳由来のタンパク質加水分解物の例として、脱脂粉乳、ホエーから以下のようにしてそれぞれのペプチドを得た。市販の脱脂粉乳、および市販の分離ホエータンパク1kgをそれぞれ温水2リットルに懸濁させ、pH7.5に調整後、それぞれにサモアーゼ(大和化成社製)40gを加え、50℃で16時間反応させた。反応後100℃で10分加熱して酵素を失活させた後、Dowex50(H+)に吸着させ、水洗、アンモニア水溶出によりペプチド区分を得た。減圧濃縮してアンモニアを除去後、凍結乾燥して脱脂粉乳ペプチド270g(試料1)、分離ホエータンパクペプチド333g(試料2)を得た。
Embodiments of the present invention will be described below with reference to production examples and examples.
(Production Example 1)
As an example of protein hydrolyzate derived from livestock milk, each peptide was obtained from skim milk powder and whey as follows. Commercially available skim milk powder and 1 kg of commercially available separated whey protein were each suspended in 2 liters of warm water, adjusted to pH 7.5, 40 g of Samoaze (manufactured by Daiwa Kasei Co., Ltd.) was added to each, and reacted at 50 ° C for 16 hours. . After the reaction, the enzyme was inactivated by heating at 100 ° C. for 10 minutes, adsorbed on Dowex 50 (H + ), washed with water, and eluted with aqueous ammonia to obtain a peptide segment. After concentration under reduced pressure to remove ammonia, lyophilized to obtain 270 g (sample 1) of skim milk powder peptide and 333 g of separated whey protein peptide (sample 2).

次に、上記製造例で得られた各試料の血管拡張効果を確認した実施例および使用例を示す。   Next, examples and usage examples in which the vasodilator effect of each sample obtained in the above production example was confirmed will be shown.

(実施例1)
体重1.5〜1.8kgの9週齢の雄ウサギ(Slc:JW・CSK)を1週間予備飼育後、実験に供した。飼育室は温度22℃±1℃、湿度50%、12時間サイクルの明暗周期とし、餌はLab Diet 5L95(日本SLC社製)を自由摂餌させ、水も自由に与えた。なお、試料を与える前は2時間絶食させた。体重1kg当たり試料1000mgを3〜10mlの生理食塩水に溶かし、経口ゾンデで強制摂取させた。
Example 1
A 9-week-old male rabbit (Slc: JW · CSK) weighing 1.5 to 1.8 kg was subjected to preliminary breeding for one week and then subjected to the experiment. The breeding room had a temperature of 22 ° C. ± 1 ° C., a humidity of 50%, and a light / dark cycle of 12 hours cycle. The sample was fasted for 2 hours before giving the sample. A sample of 1000 mg per kg body weight was dissolved in 3 to 10 ml of physiological saline and forcibly ingested with an oral sonde.

ウサギの耳の血管状態測定は次のようにして行った。ウサギを採血箱に固定後、ウサギが落ち着き、耳血管の変化が見られなくなった時点でデジタルカメラで撮影し、この時点を0分とした。試料を摂取後10分後から写真撮影を開始し、血管の拡張が沈静化するまで10分おきに撮影を続けた。得られた写真を面積計算ソフトLIA32で面積計算を行い、数値化した。   The blood vessel state of the rabbit ear was measured as follows. After fixing the rabbit in the blood collection box, when the rabbit settled down and no change in the ear blood vessel was observed, the digital camera was used to take a picture, and this time was set to 0 minutes. Photographing was started 10 minutes after the sample was ingested, and photographing was continued every 10 minutes until the dilation of the blood vessels subsided. The obtained photograph was subjected to area calculation with area calculation software LIA32 and digitized.

以上の測定を、製造例1で得た試料1〜2について行い、結果をグラフ化して図1に示した。図はタテ軸に測定血管断面積を0分の場合を1として数値化したものを示し、その時間経過後の変化を図示したものである。その結果、いずれの試料を用いてもウサギの耳血管拡張作用のあることが認められた。   The above measurement was performed on Samples 1 and 2 obtained in Production Example 1, and the results were graphed and shown in FIG. In the figure, the measured blood vessel cross-sectional area on the vertical axis is shown as a numerical value with 1 as the case of 0 minutes, and the change after the lapse of time is illustrated. As a result, it was confirmed that any sample was used to have an ear vasodilatory effect in rabbits.

(実施例2)
試料1〜2をそれぞれ80%、還元麦芽糖水飴10%、デキストリン7%、蔗糖脂肪酸エステル3%(いずれも重量%)含む300mg重量の錠剤をそれぞれ製造した。
(Example 2)
300 mg weight tablets each containing 80% of Samples 1 and 2, 10% of reduced maltose starch syrup, 7% dextrin, and 3% sucrose fatty acid ester (both by weight) were produced.

(実施例3)
実施例2に記載した試料1〜2を含む錠剤を服用した後の指先の温度を測定した。試験はボランテアの中で冷え症の解消、または軽減の効果のあった人から10人のボランテアを選び、複数日にわたって試験した。試験は朝食抜きで、20℃、湿度50%に調整した部屋に入って1時間経過後から行い、試料1〜2を含むそれぞれの錠剤6錠を水50mlと共に服用して、手指先温度の変化を服用30分経過後サーミスタ温度計で測定し、0時間からの上昇温度で表記した。なお、1試料について2人のボランテアが試験し、その平均値を記録した。

Figure 2006348050
(Example 3)
The temperature of the fingertips after taking the tablets containing Samples 1-2 described in Example 2 was measured. In the test, 10 volunteers were selected from those who were effective in relieving or alleviating coldness among volunteers, and they were tested over multiple days. The test was conducted without breakfast, after entering the room adjusted to 20 ° C and humidity 50%, after 1 hour, and taking 6 tablets each containing 1 to 2 samples with 50 ml of water and changing the fingertip temperature. Was measured with a thermistor thermometer after 30 minutes of dosing, and expressed as the temperature rising from 0 hours. Two volunteers were tested for one sample, and the average value was recorded.
Figure 2006348050

ウサギの耳について行なった乳類由来ペプチドの血管拡張作用の実験データを示すグラフ。The graph which shows the experimental data of the vasodilatory effect | action of the peptide derived from milk performed about the ear of the rabbit.

Claims (2)

脱脂粉乳およびホエーから選ばれたミルクタンパク由来のタンパク質を加水分解して得られるペプチドを有効成分とする血管拡張による血流促進性医薬組成物。   A pharmaceutical composition for promoting blood flow by vasodilation, comprising as an active ingredient a peptide obtained by hydrolyzing a protein derived from milk protein selected from skim milk powder and whey. 脱脂粉乳およびホエーから選ばれたミルクタンパク由来のタンパク質を加水分解して得られるペプチドを有効成分とする血管拡張による血流促進性健康食品組成物。   A blood flow promoting health food composition by vasodilation comprising a peptide obtained by hydrolyzing a protein derived from milk protein selected from skim milk powder and whey.
JP2006254370A 2006-09-20 2006-09-20 Medicine and health food composition for promoting bloodstream by vasolidation Pending JP2006348050A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006254370A JP2006348050A (en) 2006-09-20 2006-09-20 Medicine and health food composition for promoting bloodstream by vasolidation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006254370A JP2006348050A (en) 2006-09-20 2006-09-20 Medicine and health food composition for promoting bloodstream by vasolidation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003035063A Division JP4505707B2 (en) 2003-02-13 2003-02-13 Pharmaceutical composition for the treatment of stiff shoulders or coldness due to vasodilation

Publications (1)

Publication Number Publication Date
JP2006348050A true JP2006348050A (en) 2006-12-28

Family

ID=37644230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006254370A Pending JP2006348050A (en) 2006-09-20 2006-09-20 Medicine and health food composition for promoting bloodstream by vasolidation

Country Status (1)

Country Link
JP (1) JP2006348050A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011073973A (en) * 2009-09-29 2011-04-14 Shiseido Co Ltd Composition for ameliorating fatigue for menopause

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06298794A (en) * 1993-04-16 1994-10-25 Nippon Synthetic Chem Ind Co Ltd:The Purification of angiotensin conversion enzyme inhibiting peptide
JP2001211895A (en) * 2000-02-04 2001-08-07 Kenji Kida Method of producing physiologically active peptide
JP2002255846A (en) * 2001-02-26 2002-09-11 Sunstar Inc Oral composition
JP2002371011A (en) * 2001-06-13 2002-12-26 T Hasegawa Co Ltd Blood fluidity improving agent
JP2003267995A (en) * 2002-03-13 2003-09-25 Suetsuna Yoko New heptapeptide and inhibitor of angiotensin converting enzyme
JP2003284551A (en) * 2002-03-29 2003-10-07 National Institute Of Advanced Industrial & Technology Angiotensin i converting enzyme inhibitor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06298794A (en) * 1993-04-16 1994-10-25 Nippon Synthetic Chem Ind Co Ltd:The Purification of angiotensin conversion enzyme inhibiting peptide
JP2001211895A (en) * 2000-02-04 2001-08-07 Kenji Kida Method of producing physiologically active peptide
JP2002255846A (en) * 2001-02-26 2002-09-11 Sunstar Inc Oral composition
JP2002371011A (en) * 2001-06-13 2002-12-26 T Hasegawa Co Ltd Blood fluidity improving agent
JP2003267995A (en) * 2002-03-13 2003-09-25 Suetsuna Yoko New heptapeptide and inhibitor of angiotensin converting enzyme
JP2003284551A (en) * 2002-03-29 2003-10-07 National Institute Of Advanced Industrial & Technology Angiotensin i converting enzyme inhibitor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011073973A (en) * 2009-09-29 2011-04-14 Shiseido Co Ltd Composition for ameliorating fatigue for menopause

Similar Documents

Publication Publication Date Title
KR100734721B1 (en) Vasodilator pharmaceutical preparation and health food composition
CN102224891A (en) Sugar alcohol honey apple jam and preparation method thereof
CN101238904B (en) Chickpea bean sprout juice tea and preparation method and application
JP2004238365A (en) Skin beautifying agent, and beauty and health food
JPH09252746A (en) Nutrient-supplementing food
JP2007222116A (en) Health food and drink
JP2002034592A (en) Method for producing protein-zinc readily absorbable in body
JP2010030975A (en) Bee larva solubilized product, preparation method thereof, and pharmaceutical product, cosmetic, or food and drink containing the bee larva solubilized product
JP7428480B2 (en) Compositions for improving sleep and foods, medicines, and feed containing the compositions
JP2006348049A (en) Medicine and health food composition for promoting bloodstream by vasolidation
JP2001002583A (en) Blood sugar level increase inhibitor
WO2007090504A1 (en) Hydrolysed collagen and uses therof
CN105996057A (en) Fruit and egg white peptide tablets and preparing method thereof
JP4053686B2 (en) Bioactive health food
JP2006348050A (en) Medicine and health food composition for promoting bloodstream by vasolidation
JP2006348051A (en) Medicine and health food composition for promoting bloodstream by vasolidation
JPS5888317A (en) Product extracted from invertebrate marine animal and preparation
JP5312780B2 (en) Food / drink and pharmaceutical composition for reducing blood ammonia concentration
JP2006271357A (en) Amino acid composition
JP2001048794A (en) Health food and medicinal composition which contain mixture of powder originated from leaf of mulberry and powder originated from oyster and is used for treating niddm
JP3605528B2 (en) Weight gain inhibitor
JP2019041696A (en) Oral composition
JP2003024008A (en) Food
CN1331407C (en) Method for preparing contg. micron ginseng and antler etc. with tonifying-kidney and eliminating-fatigue functions
CN107198243A (en) A kind of underflow health products containing composite enzyme

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100309